In gliomas, depending on the tumor histopathology and the patient’s clinical features, this integrated diagnosis may require assessing the tumor for IDH1 and IDH2 (IDH), H3F3A, and BRAF mutations, as well as the 1p/19q codeletion [5]. Here, IDH2 is linked to glioma.